WO2018077889A1 - Compositions comprising linsitinib - Google Patents

Compositions comprising linsitinib Download PDF

Info

Publication number
WO2018077889A1
WO2018077889A1 PCT/EP2017/077188 EP2017077188W WO2018077889A1 WO 2018077889 A1 WO2018077889 A1 WO 2018077889A1 EP 2017077188 W EP2017077188 W EP 2017077188W WO 2018077889 A1 WO2018077889 A1 WO 2018077889A1
Authority
WO
WIPO (PCT)
Prior art keywords
acne
growth factor
insulin
pharmaceutically acceptable
compound
Prior art date
Application number
PCT/EP2017/077188
Other languages
French (fr)
Inventor
Jordi RIUS CAPALVO
Jacob Gonzalez Rodriguez
Original Assignee
Almirall, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall, S.A. filed Critical Almirall, S.A.
Publication of WO2018077889A1 publication Critical patent/WO2018077889A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Definitions

  • compositions comprising linsitinib
  • the present invention relates to the use of linsitinib in treating acne, and to pharmaceutical compositions comprising linsitinib.
  • Acne is a complex chronic skin disease characterized by seborrhoea, the formation of open and closed comedones (black and white heads respectively), erythematous papules and pustules and in more severe cases nodules and deep pustules.
  • Acne typically starts in early puberty, and it appears early in girls than boys (which correlates with early puberty onset in females), but more boys are affected in mid-teenage years. By 20-25 years tendency is to resolve slowly, however in a considerable number of people acne persists in adulthood. Alterations in the normal function of the pilosebaceous unit are the main pathophysiological features in acne and include follicle hyperkeratinisation, abnormal sebum production, P.
  • acnes infection and innate and acquired immune activation are also related with this pathology. Complications of acne lesions can lead to permanent scarring. Scarring usually follows deep-seated inflammatory lesion but may also occur as a result of more superficial inflamed lesions in scar-prone patients.
  • Acne is also associated to significant physiological morbidities such as poor self-image, depression and anxiety. Comparison with other chronic illnesses has shown that acne patients have levels of social, physiological and emotional disability similar to patients with asthma, epilepsy, diabetes or arthritis.
  • IGF-1 R Insulin-like growth factor 1 receptor
  • IGF-1 insulin growth factor-1
  • an insulin-like growth factor inhibitor particularly linsitinib
  • the topical administration of an insulin-like growth factor inhibitor, particularly linsitinib avoids the occurrence of the side-effects which would result from oral administration.
  • the present invention therefore provides an insulin-like growth factor inhibitor, particularly linsitinib, or a pharmaceutically acceptable salt thereof, for use in the topical treatment of dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer, more preferably selected from acne, actinic keratosis and seborrheic dermatitis; in particular for use in the topical treatment of acne.
  • dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer, more preferably selected from acne, actinic keratosis and seborrheic dermatitis; in particular for use in the topical treatment of acne.
  • the present invention also provides a topical pharmaceutical composition
  • a topical pharmaceutical composition comprising an insulin-like growth factor inhibitor, particularly linsitinib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent, for use in treating
  • dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer, more preferably selected from acne, actinic keratosis and seborrheic dermatitis; in particular for use in the topical treatment of acne.
  • an insulin-like growth factor inhibitor particularly of linsitinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined above, in the manufacture of a medicament for the topical treatment of dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer, in particular of acne ; and a method of treating dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer; more preferably selected from acne, actinic keratosis and seborrheic dermatitis; in particular a method of treating acne in a patient; which method comprises topically administering to the patient an insulin- like growth factor inhibitor, particularly linsitinib, or a pharmaceutically acceptable salt thereof, or a composition as defined above.
  • the insulin-like growth factor inhibitor is selective, i.e. it has not a significant activity on any other receptor, enzyme or
  • Linsitinib is cis-3-[8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1 ,5-a]pyrazin-3-yl]-1 - methylcyclobutanol. It has the structure:
  • the present invention provides linsitinib and pharmaceutical acceptable salts thereof for use in treating dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer, more preferably selected from acne, actinic keratosis and seborrheic dermatitis; in particular acne.
  • dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer, more preferably selected from acne, actinic keratosis and seborrheic dermatitis; in particular acne.
  • Standard principles underlying the selection and preparation of pharmaceutically acceptable salts are described, for example, in
  • Suitable pharmaceutically acceptable salts of the compounds for use in this invention include addition salts with a pharmaceutically acceptable acid such as such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid or phosphoric acid.
  • a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid or phosphoric acid.
  • Other salts may be formed with a pharmaceutically acceptable base.
  • Suitable such pharmaceutically acceptable salts include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; ammonium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts
  • the compound for use is linsitinib.
  • acne also designates comedonic acne, papulopustular acne, papulocomedonic acne, nodulocystic acne, acne conglobata, cheloid acne of the nape of the neck, recurrent miliary acne, necrotic acne, neonatal acne, occupational acne, acne rosacea, senile acne, solar acne and medication-related acne.
  • skin cancer includes squamous cell carcinoma, basal cell carcinoma, malignant melanoma.
  • the patient to be treated is a mammal.
  • the patient is a human.
  • the linsitinib, the pharmaceutically acceptable salt thereof or the pharmaceutical composition of the present invention is applied topically to the face of a patient.
  • compositions according to the invention are suitable for topical
  • compositions of the present invention may take the form of any formulation normally used for topical administration, in particular solutions, lotions, emulsions of liquid consistency, emulsions of semi-liquid consistency, emulsions of semi-solid consistency, emulsions of solid consistency, creams, gels or ointments.
  • compositions of the present invention may take the form of a gel, a lotion or a cream; more preferably a lotion or a cream; still more preferably a cream.
  • compositions for topical administration contain an oil phase.
  • the pharmaceutical compositions of the present invention are water-in-oil emulsions (i.e. emulsions wherein the water is the dispersed phase and the oil in the dispersion medium).
  • the pharmaceutical compositions of the present invention are oil-in-water emulsions (i.e. emulsions wherein the oil is the dispersed phase and the water in the dispersing medium).
  • Compositions for topical use in accordance with the invention may also contain one or more emollients, emulsifiers, thickeners and/or preservatives.
  • the emollients are typically long chain alcohols, such as cetyl alcohol, stearyl alcohol and cetearyl alcohol; hydrocarbons such as petrolatum and light mineral oil; or acetylated lanolin.
  • the total amount of emollient in the formulation is preferably about 10% to about 20%, and more preferably about 5% to about 10% by weight based on the total weight of the formulation.
  • the emulsifier is typically a nonionic surface active agent, e.g., polysorbate 60 (available from Sigma Aldrich), sorbitan monostearate, polyglyceryl-4 oleate, and
  • polyoxyethylene(4)lauryl ether or trivalent cationic Generally the total amount of emulsifier is preferably about 2% to about 14%, and more preferably about 2% to about 6% by weight based on the total weight of the formulation.
  • compositions such as Veegum.TM.K (available from R. T.
  • Vanderbilt Company, Inc. Vanderbilt Company, Inc.
  • long chain alcohols i.e. cetyl alcohol, stearyl alcohol or cetearyl alcohol
  • the total amount of thickener present is preferably about 3% to about 12% by weight based on the total weight of the formulation.
  • Preservatives such as methylparaben, propylparaben and benzyl alcohol can be present in the formulation.
  • an additional solubilizing agent such as benzyl alcohol, lactic acid, acetic acid, stearic acid or hydrochloric acid can be included in the formulation.
  • the formulation can contain a humectant such as glycerin and skin penetration enhancers such as butyl stearate.
  • a humectant such as glycerin
  • skin penetration enhancers such as butyl stearate.
  • the oil phase in an emulsion may be any oil phase normally used in emulsions for topical administration.
  • oil phases include, for example, hydrocarbon bases such as such as hard paraffin, soft paraffin, ceresine and microcrystalline wax, absorption bases such as lanolin and beeswax, emulsifying bases such as emulsifying wax and cetrimide, and vegetable oils such as olive oil, coconut oil, sesame oil, almond oil and peanut oil.
  • Other oil phases useful in accordance with the invention are mineral oil, liquid petroleum, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol and 2-octyldodecanol.
  • an emulsion comprising similar proportions of oil phase and water phase is usually deemed a cream, whereas an ointment will generally contain a substantially higher proportion of oil phase compared to water phase, for example greater than 60 wt. % oil phase, preferably greater than 70 wt. % oil phase, more preferably greater than 80 wt. % oil phase, based on the total weight of the oil phase and the water phase.
  • a lotion will generally contain a lower proportion of oil phase than a cream, for example under 25 wt.
  • % oil phase under 20 wt. % oil phase, under 15 wt. % oil phase, under 10 wt. % oil phase or under 5 wt. % oil phase, based on the total weight of the oil phase and the water phase.
  • a cream for use according to the invention comprises an oil phase and a water phase mixed together to form an emulsion.
  • the amount of water present in a cream of the invention is about 45% to about 95% by weight based on the total weight of the cream, more preferably about 55 wt. % to about 90 wt. %, even more preferably about 65 wt. % to about 80 wt. %.
  • composition is an ointment
  • ointment bases include hydrocarbon bases such as such as hard paraffin, soft paraffin, ceresine and microcrystalline wax, absorption bases such as lanolin and beeswax, water-soluble bases such as polyethylene glycols (e.g. polyethylene glycol 200, 300, 400, 3350, 4000 or 6000), propylene glycol and polypropylene glycols, emulsifying bases such as emulsifying wax and cetrimide, and vegetable oils such as olive oil, coconut oil, sesame oil, almond oil and peanut oil. Mixtures of ointment bases can of course be used.
  • hydrocarbon bases such as such as hard paraffin, soft paraffin, ceresine and microcrystalline wax
  • absorption bases such as lanolin and beeswax
  • water-soluble bases such as polyethylene glycols (e.g. polyethylene glycol 200, 300, 400, 3350, 4000 or 6000), propylene glycol and polypropylene glycols
  • the amount of ointment base present in an ointment of the invention is preferably about 60% to about 95% by weight based on the total weight of ointment, more preferably about 70 wt. % to about 90 wt. %, still more preferably about 75 wt. % to about 85 wt. %.
  • the pharmaceutical composition for use in accordance with the present invention may also be a lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Particular carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2- octyldodecanol and water.
  • the linsitinib or pharmaceutically acceptable salt thereof is present at a concentration of between 0.001 and 20% by weight (expressed as linsitinib free base), relative to the total weight of the composition, preferably between 0.01 and 10%, more preferably between 0.1 and 10% by weight, in particular 0.1 %, 0.25%, 0.5%, 0.75%, 1 %, 1.25%, 1.5%, 1.75%, 2%, 2.25%, 2.5%, 2.75%, 3%, 3.25%, 3.5%, 3.75%, 4%, 4.25%, 4.5%, 4.75%, 5%, 5.25%, 5.5%, 5.75%, 6%, 6.25%, 6.5%, 6.75%, 7%, 7.25%, 7.5%, 7.75%, 8%, 8.25%, 8.50%, 8.75%, 9%, 9.25%, 9.5%, 9.75% or 10%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a compound which is an insulin-like growth factor inhibitor or a pharmaceutically acceptable salt thereof for use in the topical treatment of dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer. The invention also relates to pharmaceutical compositions comprising the compound.

Description

Compositions comprising linsitinib
The present invention relates to the use of linsitinib in treating acne, and to pharmaceutical compositions comprising linsitinib.
Background to the Invention
Acne is a complex chronic skin disease characterized by seborrhoea, the formation of open and closed comedones (black and white heads respectively), erythematous papules and pustules and in more severe cases nodules and deep pustules. Acne typically starts in early puberty, and it appears early in girls than boys (which correlates with early puberty onset in females), but more boys are affected in mid-teenage years. By 20-25 years tendency is to resolve slowly, however in a considerable number of people acne persists in adulthood. Alterations in the normal function of the pilosebaceous unit are the main pathophysiological features in acne and include follicle hyperkeratinisation, abnormal sebum production, P. acnes infection and innate and acquired immune activation. Genetic, hormonal and diet- related factors are also related with this pathology. Complications of acne lesions can lead to permanent scarring. Scarring usually follows deep-seated inflammatory lesion but may also occur as a result of more superficial inflamed lesions in scar-prone patients.
Acne is also associated to significant physiological morbidities such as poor self-image, depression and anxiety. Comparison with other chronic illnesses has shown that acne patients have levels of social, physiological and emotional disability similar to patients with asthma, epilepsy, diabetes or arthritis.
Conventional treatments for acne include topical and systemic therapies. The most used topical treatments are based in retinoids, antibiotics, benzoyl peroxide (BPO), azelaic acid, and dapsone or combinations of retinoids with BPO or retinoids with antibiotiocs. Oral retinoids, specially isotretinoin, and oral antibiotics are usually indicated for moderate to severe acne patients. Oral treatments can be combined with topical therapies in order to increase efficacy. Insulin-like growth factor 1 receptor (IGF-1 R) is a tyrosine protein kinase receptor activated by insulin growth factor-1 (IGF-1 ), a pleiotropic trophic factor involved in the growth and maintenance of several tissues. It has now surprisingly been found that an insulin-like growth factor inhibitor, particularly linsitinib, has efficacy in reducing sebum production and/or skin cell proliferation when applied topically, which would be useful for treating dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer; more preferably selected from acne, actinic keratosis and seborrheic dermatitis; most preferably the dermatological disease is acne. The topical administration of an insulin-like growth factor inhibitor, particularly linsitinib, avoids the occurrence of the side-effects which would result from oral administration.
Summary of the Invention
The present invention therefore provides an insulin-like growth factor inhibitor, particularly linsitinib, or a pharmaceutically acceptable salt thereof, for use in the topical treatment of dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer, more preferably selected from acne, actinic keratosis and seborrheic dermatitis; in particular for use in the topical treatment of acne.
The present invention also provides a topical pharmaceutical composition comprising an insulin-like growth factor inhibitor, particularly linsitinib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent, for use in treating
dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer, more preferably selected from acne, actinic keratosis and seborrheic dermatitis; in particular for use in the topical treatment of acne. Also provided is the use of an insulin-like growth factor inhibitor, particularly of linsitinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined above, in the manufacture of a medicament for the topical treatment of dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer, in particular of acne ; and a method of treating dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer; more preferably selected from acne, actinic keratosis and seborrheic dermatitis; in particular a method of treating acne in a patient; which method comprises topically administering to the patient an insulin- like growth factor inhibitor, particularly linsitinib, or a pharmaceutically acceptable salt thereof, or a composition as defined above.
In a particularly preferred embodiment of the invention, the insulin-like growth factor inhibitor is selective, i.e. it has not a significant activity on any other receptor, enzyme or
pharmacological target.
Detailed Description of the Invention Linsitinib is cis-3-[8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1 ,5-a]pyrazin-3-yl]-1 - methylcyclobutanol. It has the structure:
Figure imgf000004_0001
The present invention provides linsitinib and pharmaceutical acceptable salts thereof for use in treating dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer, more preferably selected from acne, actinic keratosis and seborrheic dermatitis; in particular acne. Standard principles underlying the selection and preparation of pharmaceutically acceptable salts are described, for example, in
Handbook of Pharmaceutical Salts: Properties, Selection and Use, ed. P.H. Stahl & C.G. Wermuth, Wiley-VCH, 2002. Suitable pharmaceutically acceptable salts of the compounds for use in this invention include addition salts with a pharmaceutically acceptable acid such as such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid or phosphoric acid. Other salts may be formed with a pharmaceutically acceptable base. Suitable such pharmaceutically acceptable salts include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; ammonium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts, and meglumine salts.
In a preferred embodiment of the invention the compound for use is linsitinib.
As described herein the term "acne" also designates comedonic acne, papulopustular acne, papulocomedonic acne, nodulocystic acne, acne conglobata, cheloid acne of the nape of the neck, recurrent miliary acne, necrotic acne, neonatal acne, occupational acne, acne rosacea, senile acne, solar acne and medication-related acne.
As described herein the term "skin cancer" includes squamous cell carcinoma, basal cell carcinoma, malignant melanoma.
Typically the patient to be treated is a mammal. Preferably the patient is a human.
Typically, the linsitinib, the pharmaceutically acceptable salt thereof or the pharmaceutical composition of the present invention is applied topically to the face of a patient.
Pharmaceutical compositions according to the invention are suitable for topical
administration.
For topical administration the pharmaceutical compositions of the present invention may take the form of any formulation normally used for topical administration, in particular solutions, lotions, emulsions of liquid consistency, emulsions of semi-liquid consistency, emulsions of semi-solid consistency, emulsions of solid consistency, creams, gels or ointments.
Preferably the compositions of the present invention may take the form of a gel, a lotion or a cream; more preferably a lotion or a cream; still more preferably a cream.
The emulsions are obtained by dispersion of an oil phase in water (O/W) or a water phase in oil (W/O). Preferred pharmaceutical compositions for topical administration contain an oil phase. In a preferred embodiment, the pharmaceutical compositions of the present invention are water-in-oil emulsions (i.e. emulsions wherein the water is the dispersed phase and the oil in the dispersion medium). In another preferred embodiment, the pharmaceutical compositions of the present invention are oil-in-water emulsions (i.e. emulsions wherein the oil is the dispersed phase and the water in the dispersing medium). Compositions for topical use in accordance with the invention may also contain one or more emollients, emulsifiers, thickeners and/or preservatives.
The emollients are typically long chain alcohols, such as cetyl alcohol, stearyl alcohol and cetearyl alcohol; hydrocarbons such as petrolatum and light mineral oil; or acetylated lanolin. The total amount of emollient in the formulation is preferably about 10% to about 20%, and more preferably about 5% to about 10% by weight based on the total weight of the formulation. The emulsifier is typically a nonionic surface active agent, e.g., polysorbate 60 (available from Sigma Aldrich), sorbitan monostearate, polyglyceryl-4 oleate, and
polyoxyethylene(4)lauryl ether or trivalent cationic. Generally the total amount of emulsifier is preferably about 2% to about 14%, and more preferably about 2% to about 6% by weight based on the total weight of the formulation.
Pharmaceutically acceptable thickeners, such as Veegum.TM.K (available from R. T.
Vanderbilt Company, Inc.), and long chain alcohols (i.e. cetyl alcohol, stearyl alcohol or cetearyl alcohol) can be used. The total amount of thickener present is preferably about 3% to about 12% by weight based on the total weight of the formulation.
Preservatives such as methylparaben, propylparaben and benzyl alcohol can be present in the formulation.
Optionally, an additional solubilizing agent such as benzyl alcohol, lactic acid, acetic acid, stearic acid or hydrochloric acid can be included in the formulation.
Optionally, the formulation can contain a humectant such as glycerin and skin penetration enhancers such as butyl stearate. It is known to those skilled in the art that a single ingredient can perform more than one function in a composition, i.e., cetyl alcohol can serve both as an emollient and as a thickener.
The oil phase in an emulsion may be any oil phase normally used in emulsions for topical administration. Such oil phases include, for example, hydrocarbon bases such as such as hard paraffin, soft paraffin, ceresine and microcrystalline wax, absorption bases such as lanolin and beeswax, emulsifying bases such as emulsifying wax and cetrimide, and vegetable oils such as olive oil, coconut oil, sesame oil, almond oil and peanut oil. Other oil phases useful in accordance with the invention are mineral oil, liquid petroleum, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol and 2-octyldodecanol.
Those skilled in the art will understand that by varying the ratio of water to oil in an emulsion, the result could be deemed a lotion, a cream, or an ointment, by order of increasing proportion of oil. An emulsion comprising similar proportions of oil phase and water phase is usually deemed a cream, whereas an ointment will generally contain a substantially higher proportion of oil phase compared to water phase, for example greater than 60 wt. % oil phase, preferably greater than 70 wt. % oil phase, more preferably greater than 80 wt. % oil phase, based on the total weight of the oil phase and the water phase. A lotion will generally contain a lower proportion of oil phase than a cream, for example under 25 wt. % oil phase, under 20 wt. % oil phase, under 15 wt. % oil phase, under 10 wt. % oil phase or under 5 wt. % oil phase, based on the total weight of the oil phase and the water phase.
Generally, a cream for use according to the invention comprises an oil phase and a water phase mixed together to form an emulsion. Preferably, the amount of water present in a cream of the invention is about 45% to about 95% by weight based on the total weight of the cream, more preferably about 55 wt. % to about 90 wt. %, even more preferably about 65 wt. % to about 80 wt. %.
Where the composition is an ointment a pharmaceutically acceptable ointment base will be used. Examples of ointment bases include hydrocarbon bases such as such as hard paraffin, soft paraffin, ceresine and microcrystalline wax, absorption bases such as lanolin and beeswax, water-soluble bases such as polyethylene glycols (e.g. polyethylene glycol 200, 300, 400, 3350, 4000 or 6000), propylene glycol and polypropylene glycols, emulsifying bases such as emulsifying wax and cetrimide, and vegetable oils such as olive oil, coconut oil, sesame oil, almond oil and peanut oil. Mixtures of ointment bases can of course be used. The amount of ointment base present in an ointment of the invention is preferably about 60% to about 95% by weight based on the total weight of ointment, more preferably about 70 wt. % to about 90 wt. %, still more preferably about 75 wt. % to about 85 wt. %.
The pharmaceutical composition for use in accordance with the present invention may also be a lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2- octyldodecanol and water.
In the compositions for use according to the invention, the linsitinib or pharmaceutically acceptable salt thereof is present at a concentration of between 0.001 and 20% by weight (expressed as linsitinib free base), relative to the total weight of the composition, preferably between 0.01 and 10%, more preferably between 0.1 and 10% by weight, in particular 0.1 %, 0.25%, 0.5%, 0.75%, 1 %, 1.25%, 1.5%, 1.75%, 2%, 2.25%, 2.5%, 2.75%, 3%, 3.25%, 3.5%, 3.75%, 4%, 4.25%, 4.5%, 4.75%, 5%, 5.25%, 5.5%, 5.75%, 6%, 6.25%, 6.5%, 6.75%, 7%, 7.25%, 7.5%, 7.75%, 8%, 8.25%, 8.50%, 8.75%, 9%, 9.25%, 9.5%, 9.75% or 10%.

Claims

Claims
1 . A compound which is an insulin-like growth factor inhibitor or a pharmaceutically acceptable salt thereof for use in the topical treatment of dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer.
2. The compound for use according to claim 1 wherein the compound is linsitinib.
3. The compound for use according to claims 1 or 2 wherein the dermatological disease is selected from acne, actinic keratosis and seborrheic dermatitis.
4. The compound for use according to claims 1 to 3 wherein the dermatological disease is acne.
5. A pharmaceutical composition for topical administration comprising (a) an insulin-like growth factor inhibitor or a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable carrier or diluent, for use in treating dermatological diseases selected from acne, psoriasis, actinic keratosis, seborrheic dermatitis and skin cancer.
6. A pharmaceutical composition for use according to claim 5 wherein the insulin-like growth factor inhibitor is linsitinib.
7. A pharmaceutical composition for use according to claims 5 or 6 wherein the
dermatological disease is selected from acne, actinic keratosis and seborrheic dermatitis.
8. A pharmaceutical composition for use according to claims 5 to 7 wherein the
dermatological disease is acne.
9. A pharmaceutical composition for use according to claims 5 to 8, wherein the
composition is a gel, a lotion or a cream.
10. A pharmaceutical composition for use according to claims 5 to 9, wherein the insulinlike growth factor inhibitor or pharmaceutically acceptable salt thereof is present at a concentration of between 0.001 and 20% by weight, expressed as free base, relative to the total weight of the composition.
1 1 . Use of a compound which is an insulin-like growth factor inhibitor or a
pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined in any one of claims 5 to 10 in the manufacture of a medicament for the topical treatment of dermatological diseases as defined in any of claims 1 , 3 or 4.
12. Use of a compound according to claim 1 1 wherein the insulin-like growth factor inhibitor is linsitinib.
13. A method of treating dermatological diseases in a patient, which method comprises administering to the patient an insulin-like growth factor inhibitor or a
pharmaceutically acceptable salt thereof, or a composition as defined in any one of claims 5 to 10, wherein the dermatological diseases are as defined in any of claims 1 , 3 or 4.
14. A method according to claim 13 wherein the insulin-like growth factor inhibitor is linsitinib.
PCT/EP2017/077188 2016-10-24 2017-10-24 Compositions comprising linsitinib WO2018077889A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382483.2 2016-10-24
EP16382483 2016-10-24

Publications (1)

Publication Number Publication Date
WO2018077889A1 true WO2018077889A1 (en) 2018-05-03

Family

ID=57211455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/077188 WO2018077889A1 (en) 2016-10-24 2017-10-24 Compositions comprising linsitinib

Country Status (1)

Country Link
WO (1) WO2018077889A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022206339A1 (en) * 2021-04-02 2022-10-06 苏州普乐康医药科技有限公司 Application of osi-906

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001636A1 (en) * 1994-07-08 1996-01-25 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US20130158264A1 (en) * 2010-06-23 2013-06-20 Arlindo L. Castelhano Polymorphs of OSI-906
WO2014183055A1 (en) * 2013-05-10 2014-11-13 M. Alphabet 2, L.L.C. Methods of treating skin conditions using cyclolignan compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001636A1 (en) * 1994-07-08 1996-01-25 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US20130158264A1 (en) * 2010-06-23 2013-06-20 Arlindo L. Castelhano Polymorphs of OSI-906
WO2014183055A1 (en) * 2013-05-10 2014-11-13 M. Alphabet 2, L.L.C. Methods of treating skin conditions using cyclolignan compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts: Properties, Selection and Use", 2002, WILEY-VCH
I. PUZANOV ET AL: "A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors", CLINICAL CANCER RESEARCH, vol. 21, no. 4, 11 September 2014 (2014-09-11), US, pages 701 - 711, XP055359625, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-0303 *
M. LI ET AL: "Direct Inhibition of Insulin-Like Growth Factor-I Receptor Kinase Activity by (-)-Epigallocatechin-3-Gallate Regulates Cell Transformation", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION., vol. 16, no. 3, 1 March 2007 (2007-03-01), US, pages 598 - 605, XP055437764, ISSN: 1055-9965, DOI: 10.1158/1055-9965.EPI-06-0892 *
MYUNG IM ET AL: "Epigallocatechin-3-Gallate Suppresses IGF-I-Induced Lipogenesis and Cytokine Expression in SZ95 Sebocytes", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY : OFFICIAL JOURNAL OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY AND THE EUROPEAN SOCIETY FOR DERMATOLOGICAL RESEARCH, vol. 132, no. 12, 1 December 2012 (2012-12-01), US, pages 2700 - 2708, XP055437762, ISSN: 0022-202X, DOI: 10.1038/jid.2012.202 *
T. MAYER ET AL: "Drugs targeting insulin-like growth factor 1 receptor", BREAST CANCER ONLINE, vol. 12, no. 04, 1 April 2009 (2009-04-01), XP055360308, DOI: 10.1017/S1470903109990058 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022206339A1 (en) * 2021-04-02 2022-10-06 苏州普乐康医药科技有限公司 Application of osi-906

Similar Documents

Publication Publication Date Title
US6096326A (en) Skin care compositions and use
JPS63502437A (en) Oxygenated cholesterol-containing compositions and their use for the local treatment of diseases
JP2013500984A (en) Combination of dapsone and adapalen
CN102048724A (en) Benzoyl peroxide composition for treating skin
JP2002537240A (en) Methods and compositions for treating acne
JP2022511270A (en) Sirolimus-containing composition
JP2015530380A (en) Composition for treating psoriasis
EP2994120B1 (en) Alpha adrenergic agonists for the treatment of tissue trauma
JP6185575B2 (en) Method for treating skin inflammatory disease
WO2023084515A1 (en) Method of treating a skin disorder with egfr inhibitor
WO2018077889A1 (en) Compositions comprising linsitinib
IL303008A (en) Tapinroff compositions in the form of gel, paste and foam and methods of their use
WO2009084020A2 (en) Topical composition comprising halobetasol and salicylic acid
JP2020519656A (en) Topical compositions and methods for treating skin disorders
US20130165526A1 (en) Topical treatment with dapsone in g6pd-deficient patients
CN113101289A (en) Application of nicotinamide in preparation of preparation for treating hand-foot skin reaction
JP2004346076A (en) Beauty treatment method for red spots
JPH10139669A (en) Therapeutic agent for seborrhoic keratosis
JP2019512536A (en) Stable pharmaceutical composition for topical administration and use thereof
KR20190004316A (en) Treatment of Active Skin Conditions Using Agents to Target Energy Metabolism
TW201803568A (en) Compositions comprising timolol
US12336997B2 (en) Compositions and methods for treating vascular anomalies, nevus sebaceous syndrome, epidermal nevi, and neurofibromas
Kowalzick et al. An open pilot study of topical calcipotriol in seborrhoeic eczema
CA3026625A1 (en) Compositions comprising timolol and an anti-inflammatory agent
Tatu et al. Refractory Erythemato-Squamous Eruption of Facial Skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17787922

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17787922

Country of ref document: EP

Kind code of ref document: A1